Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy - Sun, Huiyan; Wang, Xinxia; Li, Yongqiang; Shen, Yingzhi; Zhang, Lin; Xu, Yingjie; Liu, Junling; Fan, Xuemei (Pharmaceutics, 2024)
Keywords: CRISPR; Drug delivery systems; Drugs; FDA approval; GalNAc-siRNA; hyperuricemia; Kidney diseases; Laboratory animals; Liver; Mortality; Potassium; Reagents; Rheumatism; Transgenic animals; Uric acid; xanthine oxidoreductase; United States--US; China; Japan; hyperuricemia; xanthine oxidoreductase; GalNAc-siRNA